GlassScriptPhysician profile
Daniel A Ekkens
NPI 1962433839
$8,320.29
in general payments reported to CMS, 2019-2025
47 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,718 · 2020: $1,971 · 2021: $2,387 · 2022: $1,005 · 2023: $465 · 2024: $516 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,825.57 | 2019-2025 | |
| Amgen INC. | $1,338.23 | 2019-2024 | Prolia, Evenity, Repatha |
| Novo Nordisk INC | $933.59 | 2019-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $693.23 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $489.07 | 2019-2022 | |
| Glaxosmithkline, LLC. | $244.23 | 2019-2022 | |
| Corcept Therapeutics | $240.19 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.14 | 2020-2025 | Jardiance, Ofev |
| Biohaven Pharmaceuticals, INC. | $210.13 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $204.90 | 2019-2024 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $196.30 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $190.65 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $86.68 | 2022 | |
| Amarin Pharma, INC. | $85.32 | 2020-2021 | |
| Daiichi Sankyo INC. | $81.03 | 2019-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ekkens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.